Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Change in Account Payables (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Change in Account Payables for 16 consecutive years, with $54437.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 77.67% year-over-year to $54437.0, compared with a TTM value of $202297.0 through Sep 2025, up 143.02%, and an annual FY2024 reading of -$733916.0, down 335.2% over the prior year.
  • Change in Account Payables was $54437.0 for Q3 2025 at China Pharma Holdings, up from -$19322.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $442807.0 in Q3 2023 and bottomed at -$505339.0 in Q2 2024.
  • Average Change in Account Payables over 5 years is -$30754.4, with a median of -$3413.0 recorded in 2022.
  • The sharpest move saw Change in Account Payables soared 3045.77% in 2023, then plummeted 414.87% in 2024.
  • Year by year, Change in Account Payables stood at $311018.0 in 2021, then dropped by 23.32% to $238485.0 in 2022, then crashed by 54.75% to $107922.0 in 2023, then plummeted by 244.32% to -$155753.0 in 2024, then skyrocketed by 134.95% to $54437.0 in 2025.
  • Business Quant data shows Change in Account Payables for CPHI at $54437.0 in Q3 2025, -$19322.0 in Q2 2025, and $322935.0 in Q1 2025.